"Cancer"

A new generation of oral selective estrogen receptor degrader, elastostat, has shown promise in clinical studies over standard second-line treatments such as fulvestrant for the treatment of patients with metastatic hormone receptor-positive breast cancer.

Everyone wants to be in good health because we all know that good health is the only way to live a better life. However, many diseases still occur frequently nowadays, so we need to know about the common diseases

Many kidney cancer patients want to know whether the disease is hereditary. It is really necessary to learn more about the disease because kidney cancer is one of the common diseases nowadays, so let's take a look at whether kidney cancer can be passed on to the next generation. What abnormalities will kidney cancer cause in the body?

Pancreatic cancer has long been known as the "king of cancers" due to its poor prognosis. However, a recent study showed that adding Mitazalimab to a modified FOLFIRINOX regimen resulted in control of over 90% of patients with metastatic pancreatic cancer, with 52% of patients experiencing significant tumour shrinkage!

Eye cancer is a very dangerous disease, and as the disease develops, it will affect the patient's body more and more, so it is important for eye cancer patients to receive timely treatment.

There are many diseases that may recur after treatment, so many head and neck cancer patients are worried about such a situation, and their frequent ruminations may cause a lot of psychological stress to them.

Stomach cancer can cause abnormal symptoms in the digestive system, even vomiting blood and black stools, so it should be treated promptly after having stomach cancer

Blood cancer is a very complicated disease and should be treated in a timely manner to improve your disease and health condition and to gradually relieve your symptoms.

Data from a trial show that adding the new drug Eganelisib to standard treatment significantly improves the length of survival for patients with triple-negative breast cancer whose disease remains unexacerbated. Patients benefited regardless of their PD-L1 status.

Preoperative oxaliplatin-fluoropyrimidine chemotherapy given to colon cancer patients did not increase the risk of perioperative complications in colon cancer patients and did reduce postoperative recurrence rates, according to the results of the international phase 3/4 FOxTROT trial.